Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

20. Februar 2019 10:30 ET | Quelle: Centre for the Commercialization of Antibodies and Biologics

CCAB announces creation of new brain cancer therapeutic company, Empirica Therapeutics, as part of its strategy to advance new early-stage life sciences companies

TORONTO, Feb. 20, 2019 (GLOBE NEWSWIRE) -- The Centre for the Commercialization of Antibodies and Biologics (CCAB) today announced a license agreement with Empirica Therapeutics Inc. aimed at...
10. September 2018 09:00 ET | Quelle: Centre for the Commercialization of Antibodies and Biologics

CCAB and Triumvira Immunologics Announce Triumvira’s License Agreement with University of Toronto for the Discovery of Antibody Drug Development Candidates

AUSTIN, Texas and HAMILTON, Ontario and TORONTO, Sept. 10, 2018 (GLOBE NEWSWIRE) -- The Centre for the Commercialization of Antibodies and Biologics (CCAB) and Triumvira Immunologics, Inc....
21. August 2018 08:30 ET | Quelle: Centre for the Commercialization of Antibodies and Biologics

CCAB Partners With ImmunoBiochem as it Launches New Co-Development Strategy to Advance Early-Stage Biotech Companies

TORONTO, Aug. 21, 2018 (GLOBE NEWSWIRE) -- The Centre for the Commercialization of Antibodies and Biologics (CCAB) and ImmunoBiochem Corporation have announced an agreement that will see CCAB...
03. April 2017 08:30 ET | Quelle: Centre for the Commercialization of Antibodies and Biologics

CCAB Signs Collaboration and License Agreement With Pionyr Immunotherapeutics Inc. to Discover Antibody Drug Development Candidates

TORONTO, April 03, 2017 (GLOBE NEWSWIRE) -- The Centre for the Commercialization of Antibodies and Biologics (CCAB), through the University of Toronto, has granted a non-exclusive license to Pionyr...